On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

PTS

6-pyruvoyltetrahydropterin synthase

The PTS gene provides instructions for making an enzyme essential for producing tetrahydrobiopterin (BH4), a crucial molecule involved in amino acid processing and neurotransmitter synthesis. The PTS gene encodes the enzyme 6-pyruvoyltetrahydropterin synthase, involved in the synthesis of tetrahydrobiopterin (BH4).

Chromosome 11q23.1 Autosomal recessive HGNC:9689 Tier C
PTS 11q23.1 p arm q arm 11

PTS is located on the long (q) arm of chromosome 11, at band 11q23.1. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 11 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The PTS gene, also known as 6-pyruvoyltetrahydropterin synthase, is integral to the human metabolic system. It provides the genetic blueprint for an enzyme that plays a critical role in the biosynthesis of tetrahydrobiopterin (BH4), a vital cofactor in several biochemical pathways.

Disruptions in the PTS gene can lead to reduced BH4 production, impacting key bodily functions, particularly those related to brain chemistry and amino acid metabolism. Understanding the PTS gene is important for individuals undergoing carrier screening for inherited metabolic conditions.

What the gene does

The primary function of the PTS gene is to direct the synthesis of the enzyme 6-pyruvoyltetrahydropterin synthase. This enzyme participates in the second step of a three-step pathway responsible for creating tetrahydrobiopterin (BH4). BH4 is an essential cofactor, meaning it helps other enzymes perform their functions effectively.

Specifically, BH4 is crucial for processing various amino acids, which are the building blocks of proteins. For instance, it collaborates with the enzyme phenylalanine hydroxylase to convert phenylalanine into tyrosine. Furthermore, BH4 is involved in the synthesis of neurotransmitters, which are chemical messengers that transmit signals between nerve cells in the brain. Adequate BH4 levels are therefore vital for normal neurological function and metabolic balance.

Video: Genetics 101

Chromosome location

The PTS gene is located on chromosome 11, specifically at position 11q23.1. This precise location on the long arm (q) of chromosome 11 helps define its position within the human genome. The gene contains several exons, which are the coding segments that are ultimately translated into the protein.

Protein structure

The PTS gene encodes a protein that is 145 amino acids in length. Domain architecture has not been experimentally characterised in detail for this protein.

Key variants

Variations within the PTS gene can alter the function or production of the 6-pyruvoyltetrahydropterin synthase enzyme. Over 45 different changes, or mutations, in the PTS gene have been identified. These genetic changes can range from single amino acid substitutions to other types of alterations that impact the enzyme's structure and activity.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for PTS.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.174_175del
Deletion
p.Val59fs Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.186+1G>A
single nucleotide variant
- Pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.243G>A
single nucleotide variant
p.Glu81= Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.245A>G
single nucleotide variant
p.Glu82Gly Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.314+2T>C
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.315-1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.331G>A
single nucleotide variant
p.Ala111Thr Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.342C>G
single nucleotide variant
p.Ile114Met Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.367C>T
single nucleotide variant
p.Pro123Ser Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
c.379C>T
single nucleotide variant
p.Leu127Phe Pathogenic/Likely pathogenic ★★☆☆ 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in the PTS gene are primarily associated with a condition known as tetrahydrobiopterin deficiency. When caused by PTS gene variants, this specific type of deficiency is referred to as 6-pyruvoyltetrahydropterin synthase (PTS) deficiency. This condition accounts for more than half of all diagnosed cases of tetrahydrobiopterin deficiency, highlighting the significant role of the PTS gene in this metabolic pathway.

No condition pages are linked to this gene yet. This does not mean it has no associated conditions.

Inheritance pattern

Conditions caused by pathogenic PTS variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous PTS carrier status across ancestry groups?

UK clinical status

The PTS gene is recognised in the UK by NHS England's Genomic Medicine Service and is included on several NHS Genomic Test Directories. It is listed as 'green' on PanelApp, indicating strong evidence for its association with various conditions. These include Dystonia, chorea or related movement disorder, childhood onset (R57), Early onset or syndromic epilepsy, Foetal anomalies (R21), Intellectual disability, Likely inborn error of metabolism (R98), Neurotransmitter disorders, and Undiagnosed metabolic disorders.

Frequently asked questions

What is the main role of the PTS gene?

The PTS gene provides instructions for making an enzyme called 6-pyruvoyltetrahydropterin synthase. This enzyme is crucial for the production of tetrahydrobiopterin (BH4), a molecule essential for processing amino acids and synthesising neurotransmitters.

What happens if the PTS gene does not function correctly?

If the PTS gene does not function correctly, it can lead to reduced production of the 6-pyruvoyltetrahydropterin synthase enzyme, resulting in tetrahydrobiopterin (BH4) deficiency. This deficiency can affect amino acid metabolism and the production of neurotransmitters, impacting neurological function.

How common are PTS gene mutations?

Over 45 different mutations in the PTS gene have been identified as causes of tetrahydrobiopterin deficiency. When this condition is caused by PTS gene mutations, it is known as 6-pyruvoyltetrahydropterin synthase (PTS) deficiency, which accounts for more than half of all tetrahydrobiopterin deficiency cases.

References

  1. Leuzzi V, Carducci CA, Carducci CL. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clinical genetics. 2010. PMID: 20059486
  2. Longo N. Disorders of biopterin metabolism. Journal of inherited metabolic disease. 2009. PMID: 19234759
  3. Wang L, Yu WM, He C. Long-term outcome and neuroradiological findings of 31 patients with 6-pyruvoyltetrahydropterin synthase deficiency. Journal of inherited metabolic disease. 2006. PMID: 16601879
  4. Thöny B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Human mutation. 2006. PMID: 16917893
  5. Kao CD, Niu DM, Chen JT. Subtle brain dysfunction in treated 6-pyruvoyl-tetrahydropterin synthase deficiency: relationship to motor tasks and neurophysiological tests. Brain & development. 2004. PMID: 15036427
  6. Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Current drug metabolism. 2002. PMID: 12003346
  7. Dudesek A, Röschinger W, Muntau AC. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. European journal of pediatrics. 2001. PMID: 11388593
  8. Liu TT, Chiang SH, Wu SJ. Tetrahydrobiopterin-deficient hyperphenylalaninemia in the Chinese. Clinica chimica acta; international journal of clinical chemistry. 2001. PMID: 11694255
  9. Thöny B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. The Biochemical journal. 2000. PMID: 10727395
  10. Auerbach G, Nar H. The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase. Biological chemistry. 1997. PMID: 9165069
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 18 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .